Diabetes (type 2) - pioglitazone (replaced by TA63)
Summary
This guidance has been replaced by Diabetes (type 2) - glitazones (review).
Guidance documents
Implementing this guidance
About this guidance
Technology appraisals TA21
Issued: March 2001
Site tools
- Skip to content
- Vision impaired
- Login
- Links
- Glossary
- Contact
- Sitemap
- Site help
- Advanced search
- Accessibility
- Disclaimer